Label Changes for:
Mobic (meloxicam) Tablets, Oral Suspension
Changes have been made to the PRECAUTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – July 2011
7 DRUG INTERACTIONS
7.8 Kayexalate (sodium polystyrene sulfonate)
- Cases of intestinal necrosis (possibly fatal) have been described in patients who received concomitant sorbitol and Kayexalate (sodium polystyrene sulfonate). Due to the presence of sorbitol in MOBIC Oral Suspension, use with Kayexalate is not recommended